Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26447771 | 0.92 | MEN1 (0.37) | MEN1KMT2ALMNAHCRTR2HCRTR1 | |
| SCHEMBL27224924 | 0.91 | MEN1 (0.37) | MEN1KMT2ALMNAHCRTR2HCRTR1 | |
| SCHEMBL24847994 | 0.88 | KMT2A (0.38) | MEN1KMT2ALMNAHCRTR2HCRTR1 | |
| SCHEMBL24847167 | 0.88 | MEN1 (0.39) | MEN1KMT2ALMNAHCRTR2HCRTR1 | |
| SCHEMBL27225524 | 0.86 | MEN1 (0.41) | MEN1KMT2ALMNAHCRTR2HCRTR1 | |
| SCHEMBL27166458 | 0.85 | MEN1 (0.37) | MEN1KMT2ALMNAHCRTR2HCRTR1 | |
| SCHEMBL31601548 | 0.84 | MEN1 (0.44) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL23832587 | 0.83 | HCRTR2 (0.40) | MEN1KMT2ALMNAHCRTR2HCRTR1 | |
| SCHEMBL23842066 | 0.83 | HCRTR2 (0.40) | MEN1KMT2ALMNAHCRTR2HCRTR1 | |
| SCHEMBL29751507 | 0.82 | LMNA (0.40) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | MEN1 1917/4885KMT2A 99/4885LMNA 4560/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | MEN1 1917/4885KMT2A 99/4885LMNA 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.